Daily Newsletter

20 November 2023

Daily Newsletter

20 November 2023

AstraZeneca launches new digital health solutions business Evinova 

The new business will offer digital technology solutions to cut down time and expenditure for new drug development.

Srivani Venna November 20 2023

AstraZeneca has launched Evenova, a new digital health solutions business, within the company to expedite innovation in the life sciences industry.

Evinova will focus on delivering internationally scaled digital products and offerings with continuing support from AstraZeneca, as well as from its strategic partnerships with contract research organisations (CROs) Parexel and Fortrea. 

The top priority of the new business will be to bring to market digital technology offerings used globally by AstraZeneca to optimise the design and delivery of clinical trials. 

This approach will cut down the time and expenditure for new drug development.

Evinova will combine the clinical and regulatory expertise gained at AstraZeneca with its capabilities in digital technology across development and strategy, developing digital products, data science and artificial intelligence among other areas.

The business also plans to seek its potential in the remote digital monitoring of patients and in digital therapeutics via a digital innovation pipeline in these sectors.

Leveraging the expertise of AstraZeneca in new therapeutics development and insights from patients and clinical researchers, Evinova will design technology solutions for pharma, biotech companies and CROs. 

These solutions, which will support clinical research across the globe, are currently used to deliver clinical trials sponsored by AstraZeneca in more than 40 countries.

AstraZeneca CEO Pascal Soriot stated: “The future of medicine development can be accelerated with digital solutions. 

“We believe Evinova’s combination of scientific expertise and track record in developing AI-enabled digital technologies at scale provides a real opportunity to fundamentally improve patient care, drive healthcare transformation and reduce carbon emissions.”

Acute Renal Failure (ARF) - Market Landscape

Only a handful of approved therapeutic drugs are currently available for the treatment of ARF, all belonging to the solute carrier family 12 member 1 inhibitor. The clinical trial space in ARF consists of almost an equal mix of commercial as well as academic sponsors, with Iran and the US emerging as the key countries for conducting Phase III trials. While the current marketed drug space for ARF has only a handful of treatment options, currently available mid-to-late-stage pipeline drugs are likely to pave the way for a new treatment approach in the future.

Newsletters by sectors


Sign up to the newsletter: In Brief

Your corporate email address *
First name *
Last name *
Company name *
Job title *
Vist our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Thank you for subscribing

View all newsletters from across the GlobalData Media network.